MitoBio Pharma

MitoBio Pharma is a private biopharmaceutical company dedicated to the development of novel small molecule therapeutics that modulate mitochondrial function and cellular metabolism. Founded in 2012 as a spin-out from Rutgers University, the company utilizes a proprietary platform of mitochondrial uncouplers, termed "miunins," to treat metabolic disorders and cancer. Their primary focus is on non-alcoholic steatohepatitis (NASH) and type 2 diabetes, where their lead candidates aim to reduce hepatic lipid accumulation and improve insulin sensitivity. Additionally, MitoBio Pharma is exploring the application of its technology in various oncology indications, including hepatocellular carcinoma and metastatic cancers. The company operates through a strategic partnership with Rutgers University and is backed by Mega Hill Investment.